DelveInsight’s “Open-Angle Glaucoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Open-Angle Glaucoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Open-Angle Glaucoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Open-Angle Glaucoma: An Overview
Glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects, due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma (OAG) and narrow-angle glaucoma.
The OAG is primarily divided into two subtypes, i.e., Primary open-angle glaucoma (POAG) and Secondary open-angle glaucoma. POAG is a subset of glaucoma defined by an open, normal-appearing anterior chamber angle and raised intraocular pressure (IOP), with no other underlying disease. In Secondary open-angle glaucoma, there is an identifiable cause of increased eye pressure, resulting in optic nerve damage and vision loss.
Open-Angle Glaucoma Market Key Facts
-
A recent review estimated the global number of Primary open-angle glaucoma (POAG) cases in 2013 at 44 million, rising to 53 million in 2020 due to population aging.
-
Primary open-angle glaucoma (POAG) is the most common type of glaucoma, accounting for three-quarters (74%) of all glaucoma cases.
-
DelveInsight’s analysts have assessed that the total prevalent population of Glaucoma in the 7MM was around 10 million in 2018. In addition to this, it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG.
-
According to DelveInsight’s analysis, females are affected more than males in the case of open-Angle Glaucoma.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Open-Angle Glaucoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Open-Angle Glaucoma market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Open-Angle Glaucoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Open-Angle Glaucoma Epidemiology Segmentation
-
Total Diagnosed Prevalent Population of Open-Angle Glaucoma
-
Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma
-
Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma
-
Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma
Open-Angle Glaucoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Open-Angle Glaucoma market or expected to get launched during the study period. The analysis covers Open-Angle Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Open-Angle Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/open-angle-glaucoma-market
Open-Angle Glaucoma Therapeutics Analysis
There are approx. 20+ key companies which are developing therapies for Open-Angle Glaucoma. Currently, Ocular Therapeutix has its drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Open-Angle Glaucoma Market include
• Allergan
• SPARC Limited
• Laboratorios Sophia
• Nicox Ophthalmics
• Qlaris Bio
• Ocular Therapeutix
• SALVAT
• Aerpio Pharmaceuticals
• Ocularis Pharma
• PolyActiva
• AbbVie
• Annexon
• Skye Bioscience
• GrayBug
• Quark Pharmaceuticals
And many others.
Open-Angle Glaucoma Therapies covered in the report include:
• Durysta (Bimatoprost SR)
• PDP–716
• PRO-122
• DE-130A
• QLS-101
• Razuprotafib
And others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/open-angle-glaucoma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Open-Angle Glaucoma Competitive Intelligence Analysis
4. Open-Angle Glaucoma Market Overview at a Glance
5. Open-Angle Glaucoma Disease Background and Overview
6. Open-Angle Glaucoma Patient Journey
7. Open-Angle Glaucoma Epidemiology and Patient Population
8. Open-Angle Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Open-Angle Glaucoma Unmet Needs
10. Key Endpoints of Open-Angle Glaucoma Treatment
11. Open-Angle Glaucoma Marketed Products
12. Open-Angle Glaucoma Emerging Therapies
13. Open-Angle Glaucoma Seven Major Market Analysis
14. Attribute Analysis
15. Open-Angle Glaucoma Market Outlook (7 major markets)
16. Open-Angle Glaucoma Access and Reimbursement Overview
17. KOL Views on the Open-Angle Glaucoma Market.
18. Open-Angle Glaucoma Market Drivers
19. Open-Angle Glaucoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/open-angle-glaucoma-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Primary Progressive Multiple Sclerosis (PPMS) Market
“Primary Progressive Multiple Sclerosis (PPMS) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Primary Progressive Multiple Sclerosis Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/